ADHD
The Akili team took the latest trends in video game development paired with user-feedback to create the updates.
KT will also open its digital healthcare platform for NeuroSigma's advanced monitoring and AI analysis services.
The platform can give users resources about treatment, educational plans and coping with ADHD.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
Mightier is teaming up with Magellan Health to conduct the study.
The company is looking to expand specifically in the Chinese market, inking a deal with payer and provider Ping An.
The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.
Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.
The home-based pilot program will see 20 children each receive a take-home kit that includes Neeuro’s brainwave-reading SenzeBand and a Samsung tablet with the preloaded CogoLand game.
Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.